ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
Status: Recruiting
Location: See all (19) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants must agree to follow the reproductive criteria as outlined in the protocol
• Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Locations
United States
Colorado
UCHealth Harmony
RECRUITING
Fort Collins
UCHealth Poudre Valley Hospital
RECRUITING
Fort Collins
UCHealth Greeley Hospital
RECRUITING
Greeley
Longs Peak Hospital
RECRUITING
Longmont
UCHealth Longs Peak Medical Center
RECRUITING
Longmont
UCHealth - Medical Center of the Rockies
RECRUITING
Loveland
Michigan
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
NOT_YET_RECRUITING
Detroit
Texas
St. David's South Austin Medical Center
RECRUITING
Austin
Other Locations
Canada
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITING
Calgary
Cross Cancer Institute
RECRUITING
Edmonton
McGill University Health Centre
RECRUITING
Montreal
China
Peking University Third Hospital
RECRUITING
Beijing
Sun Yat-sen University Cancer Center
RECRUITING
Guangzhou
The first Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING
Hangzhou
Shandong Provincial Hospital
RECRUITING
Jinan
Japan
University Hospital,Kyoto Prefectural University of Medicine
RECRUITING
Kyoto
Japanese Red Cross Medical Center
RECRUITING
Shibuya-ku
Taiwan
National Taiwan University Hospital
RECRUITING
Taipei
Taipei Veterans General Hospital
RECRUITING
Taipei
Contact Information
Primary
Pfizer CT.gov Call Center
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Time Frame
Start Date: 2023-10-03
Estimated Completion Date: 2032-02-22
Participants
Target number of participants: 80
Treatments
Experimental: Elranatamab
Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
Related Therapeutic Areas
Sponsors
Leads: Pfizer